Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Bone and Calcium Disorders
What is the recommended duration of Burosumab therapy for treating X-linked hypophosphatemia and how is response to therapy monitored?
Related Questions
Is there a role for monitoring PTH levels in patients with advanced chronic kidney disease who are receiving denosumab to assess for adynamic bone disease?
What 24 hr urine calcium cut off value do you use for recommending parathyroidectomy in patients with asymptomatic hyperparathyroidism?
How do you approach management of osteoporosis in patients post lung transplant?
How do you approach a patient with Paget’s disease of bone with elevated alkaline phosphatase and history of chronic kidney disease?
Can FHH present with marked hypercalcemia (e.g., >12 mg/dL)?
Can you use bisphosphonates in a patient with osteoporosis who has had prior avascular necrosis of TMJ due to steroid use?
What treatment options are there for Fanconi syndrome-induced osteoporosis in young female patients outside of electrolyte and mineral replacement?
How do you approach a patient with elevated bone specific ALP (>2X the normal limit), but no other evidence of Paget's disease?
Does vitamin D supplementation in primary hyperparathyroidism increase the risk of kidney stones?
Are there certain patients with primary hyperparathyroidism for whom you would consider percutaneous ablation of a parathyroid adenoma over surgical parathyroidectomy?
